ReviewEye and brain2012
Neuro-ophthalmic sarcoidosis.
Review in Eye and brain, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Review of atypical optic neuritis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- Article
- Isolated Optic Disc Granuloma as a Presenting Sign of Sarcoidosis.Ocular immunology and inflammation · 2024Article
- Beyond Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies: Alternative Causes of Optic Neuritis.International journal of molecular sciences · 2023Review
- Recurrent multiple eye muscle palsy as a first sign of sarcoidosis.GMS ophthalmology cases · 2023Article
- An Unusual Presentation of Neurosarcoidosis.The American journal of case reports · 2022Article
- Subretinal peripapillary biopsy-proven sarcoidosis: a case report.International journal of retina and vitreous · 2022Article
- Optic nerve head sarcoidosis mimicking an intraocular tumour, and occurring as the first manifestation of neuro-ocular sarcoidosis.American journal of ophthalmology case reports · 2020Article
- Neurosarcoidosis presenting as CRVO combined CRAO: a biopsy-proven case report of a Chinese patient.BMC ophthalmology · 2020Article
- Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study.Journal of clinical medicine · 2020Article
- Optic Neuritis.Continuum (Minneapolis, Minn.) · 2019Review
- Treatment options for atypical optic neuritis.Indian journal of ophthalmology · 2014Review
- Acute Optic Neuritis: An Update on Approach and Management.Journal of ophthalmic & vision researchReview
- Optic Perineuritis Mimicking Optic Nerve Sheath Meningioma: A Case Series.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-ophthalmic disease occurs in about a third of patients with neurosarcoidosis. Optic nerve involvement is the most common manifestation, but other cranial nerves and the optic chiasm can be involved. However, there are several other common diseases that cause optic neuropathy, including multiple sclerosis. The diagnosis of sarcoidosis can often be made based on the multi-organ nature of the disease and ancillary testing. Most patients with neuro-ophthalmic sarcoidosis require systemic therapy. While corticosteroids are usually the first step in therapy, cytotoxic agents such as methotrexate and azathioprine have been useful as steroid-sparing agents for chronic disease. The monoclonal antibodies directed against tumor necrosis factor have been reported as effective in refractory cases of neuro-ophthalmic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.